Publications by authors named "Mandy Parson"

Claim this Profile
B
Benefit-Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia.
Anthony Stein, Janet L Franklin, Victoria M Chia, Deborah Arrindell, William Kormany, Mandy Parson

Drug Saf· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer.
George R Blumenschein, Karen Reckamp, G Joe Stephenson, Timothy O'Rourke, Gregory Gladish, Mandy Parson

Clin Cancer Res· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial of irinotecan in combination with amifostine in patients with advanced colorectal carcinoma.
Maria L Delioukina, Diane Prager, Mandy Parson, J Randolph Hecht, Peter Rosen

Cancer· April 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors.
Bart C Kuenen, Lee Rosen, Egbert F Smit, Mandy R N Parson, Marcel Levi

J Clin Oncol· March 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis